How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?

Given that cardiovascular safety liabilities remain a major cause of drug attrition during preclinical and clinical development, adverse drug reactions, and post-approval withdrawal of medicines, the Medical Research Council Centre for Drug Safety Science hosted a workshop to discuss current challen...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Laverty, HG, Benson, C, Cartwright, EJ, Cross, MJ, Garland, C, Hammond, T, Holloway, C, McMahon, N, Milligan, J, Park, BK, Pirmohamed, M, Pollard, C, Radford, J, Roome, N, Sager, P, Singh, S, Suter, T, Suter, W, Trafford, A, Volders, PGA, Wallis, R, Weaver, R, York, M, Valentin, JP
Formato: Artigo
Lenguaje:Inglês
Publicado: Blackwell Publishing Ltd 2011
Materias:
Reviews
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3111672/
https://ncbi.nlm.nih.gov/pubmed/21306581
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1476-5381.2011.01255.x
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares